Johnson & Johnson will seek authorization for a booster shot this week, according to The New York Times, which cited Unidentified officials familiar with the company’s plans.
The news that the company will seek clearance from the Food and Drug Administration (FDA) comes amid concerns about the efficacy of its single-shot Covid-19 vaccine.
The FDA has confirmed that Its expert advisory committee is scheduled to discuss Johnson & Johnson’s vaccine booster shots during their October 14-15 meetings.
“The fact that the Johnson & Johnson advisory committee meeting was scheduled even before the company submitted an application to the Food and Drug Administration reflects a particular sense of urgency in the Biden administration to provide more protection to recipients of that vaccine ”, The New York Times reported, noting that a recent study The Centers for Disease Control and Prevention (CDC) found that Johnson & Johnson’s single-dose vaccine was only 71% effective in preventing hospitalizations.
Alan is a writer, editor, and news junkie based in New York.